Trial Profile
ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB-II
- Sponsors Abbott Vascular
- 25 Sep 2018 Five-year clinical results will be presented for the first time at TCT, two full years after scaffold resorption as per trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 25 Sep 2018 Status changed from active, no longer recruiting to completed as per trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 25 Sep 2018 Trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics